Fulcrum Therapeutics Inc (FULC)
7.59
+0.05
(+0.66%)
USD |
NASDAQ |
May 08, 16:00
7.605
+0.02
(+0.20%)
After-Hours: 20:00
Fulcrum Therapeutics Revenue (TTM): 2.805M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.805M |
| September 30, 2023 | 2.619M |
| June 30, 2023 | 3.043M |
| March 31, 2023 | 4.045M |
| December 31, 2022 | 6.342M |
| September 30, 2022 | 10.72M |
| June 30, 2022 | 14.47M |
| Date | Value |
|---|---|
| March 31, 2022 | 16.97M |
| December 31, 2021 | 19.16M |
| September 30, 2021 | 18.33M |
| June 30, 2021 | 15.24M |
| March 31, 2021 | 12.86M |
| December 31, 2020 | 8.823M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
2.619M
Minimum
Sep 2023
19.16M
Maximum
Dec 2021
10.42M
Average
10.72M
Median
Sep 2022
Revenue (TTM) Benchmarks
| Pfizer Inc | 55.09B |
| NovaBay Pharmaceuticals Inc | 14.73M |
| Palatin Technologies Inc | 7.098M |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |